Compare e l f Beauty Inc (ELF) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs TG Therapeutics Inc — how do they compare? e l f Beauty Inc trades at $108.32 (market cap $6.25B), while TG Therapeutics Inc trades at $55.15 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, e l f Beauty Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 25 Days and TG Therapeutics Inc for 15 Days on average.
| ELF | TGTX | |
|---|---|---|
Market Cap | $6.25B | $8.16B |
Volume | 1,099,552 | 1,735,121 |
Sector | Consumer Staples | Health |
52-Week High | $144.97 | $59.06 |
52-Week Low | $49.57 | $26.94 |
Typical Hold Time | 25 Days | 15 Days |
Enterprise Value | $6.84B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $107.95, up 2.78% with bullish technical signals and strong earnings beats. The stock shows robust revenue growth reaching $1.31B in 2025, though net margins compressed to 3.38% in 2026. Recent expansion includes rhode brand launches in Europe via Sephora and innovative marketing through original music albums. Analyst sentiment leans positive with 48% buy ratings despite a consensus price target of $95.91 below current levels.
Outlook remains growth-focused with international expansion driving opportunities, but premium valuation (P/E 108) and margin pressure pose risks. Institutional accumulation and technical strength support near-term upside, though investors should monitor execution on global growth initiatives against high expectations.
TG Therapeutics (TGTX) trades at $54.96, up 3.8% with strong fundamentals including 82.37% gross margins and 100.28% ROE, though recent earnings misses and a negative cash flow of -$100.70M in 2025 raise concerns. Technical indicators show bearish momentum with support at $51-$52, while news highlights BRIUMVI's market share gains and potential acquisition interest.
The outlook remains mixed: analyst consensus is bullish with an $80.50 price target, but risks include ongoing litigation, earnings volatility, and competitive pressures. Upside potential hinges on BRIUMVI's continued growth and pipeline advancements, making TGTX a high-risk, high-reward biotech play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
